Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07770828 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Phase 3 Study to Assess Efficacy, Safety & Tolerability of OCU410 For Geographic Atrophy Secondary to Dry AMD

StatusRecruiting
PhasePhase 3
SponsorOcugen
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study sites: 1 to 3v2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Ocugen
6 trials monitored
See all monitored trials
This study is a Phase 3 multicenter, randomized, controlled, assessor blinded, adaptive study in which subjects will be randomized in a 2:1(OCU410: control) ratio to treatment arm or control arm
Trial Details
NCT Number NCT07770828
Lead Sponsor Ocugen
Conditions
(from sponsor)		 Dry Age-related Macular Degeneration
Enrollment 237 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov